key: cord-0709413-rucmn1n1
authors: Keshavarz, Behnam; Wiencek, Joesph R.; Workman, Lisa J.; Straesser, Matthew D.; Muehling, Lyndsey M.; Canderan, Glenda; Drago, Fabrizio; Bonham, Catherine A.; Sturek, Jeffrey M.; Ramani, Chintan; McNamara, Coleen A.; Woodfolk, Judith A.; Kadl, Alexandra; Platts-Mills, Thomas A.E.; Wilson, Jeffrey M.
title: Quantitative Measurement of IgG to Severe Acute Respiratory Syndrome Coronavirus-2 Proteins Using ImmunoCAP
date: 2021-02-23
journal: Int Arch Allergy Immunol
DOI: 10.1159/000514203
sha: 1b19a62b094beee0ea384272be0bf5a9d007c644
doc_id: 709413
cord_uid: rucmn1n1

BACKGROUND: Detailed understanding of the immune response to severe acute respiratory syndrome coronavirus (SARS-CoV)-2, the cause of coronavirus disease 2019 (CO­VID-19) has been hampered by a lack of quantitative antibody assays. OBJECTIVE: The objective was to develop a quantitative assay for IgG to SARS-CoV-2 proteins that could be implemented in clinical and research laboratories. METHODS: The biotin-streptavidin technique was used to conjugate SARS-CoV-2 spike receptor-binding domain (RBD) or nucleocapsid protein to the solid phase of the ImmunoCAP. Plasma and serum samples from patients hospitalized with COVID-19 (n = 60) and samples from donors banked before the emergence of COVID-19 (n = 109) were used in the assay. SARS-CoV-2 IgG levels were followed longitudinally in a subset of samples and were related to total IgG and IgG to reference antigens using an ImmunoCAP 250 platform. RESULTS: At a cutoff of 2.5 μg/mL, the assay demonstrated sensitivity and specificity exceeding 95% for IgG to both SARS-CoV-2 proteins. Among 36 patients evaluated in a post-hospital follow-up clinic, median levels of IgG to spike-RBD and nucleocapsid were 34.7 μg/mL (IQR 18–52) and 24.5 μg/mL (IQR 9–59), respectively. Among 17 patients with longitudinal samples, there was a wide variation in the magnitude of IgG responses, but generally the response to spike-RBD and to nucleocapsid occurred in parallel, with peak levels approaching 100 μg/mL, or 1% of total IgG. CONCLUSIONS: We have described a quantitative assay to measure IgG to SARS-CoV-2 that could be used in clinical and research laboratories and implemented at scale. The assay can easily be adapted to measure IgG to mutated COVID-19 proteins, has good performance characteristics, and has a readout in standardized units.

Serological assays that quantify antibodies specific for severe acute respiratory syndrome coronavirus (SARS-CoV)-2 represent an important tool in the investigation of the epidemiology and immunology of this novel coronavirus, the cause of the coronavirus disease 2019 (CO-VID-19) pandemic [1] [2] [3] . Many studies have reported on antibodies specific for SARS-CoV-2, and however, most of the assays used in these studies have had qualitative and/or semiquantitative readouts and very few have used standardized units (e.g., µg/mL) [4] [5] [6] [7] [8] [9] [10] [11] [12] . The Immuno-CAP assay developed by Phadia/Thermo Fisher is often considered the gold standard for quantitative detection of IgE antibodies to allergens in both clinical and research laboratories. The platform was designed for IgE detection but can also be used to quantify other antibody isotypes/ subclasses including IgG and IgG4 [13, 14] . The assay has high accuracy, consistency, and reproducibility and has a readout in standardized units (i.e., IU/mL for IgE and μg/ mL for IgG and IgG4) [15] . A major strength of the Im-munoCAP is that antibodies specific for multiple antigenic targets can readily be assessed in parallel. With the emergence of the coronavirus pandemic, we asked whether the ImmunCAP could be used to measure IgG to SARS-CoV-2 proteins. Here, we describe a novel assay that takes advantage of the biotin-streptavidin technique to link commercially available recombinant SARS-CoV-2 proteins to the high-capacity absorbent solid phase of the ImmunoCAP [16, 17] . The assay was developed using plasma and serum samples from established COVID-19 patients and also samples from control subjects banked prior to the pandemic. Our results suggest that the Immu-noCAP-based approach has good performance characteristics and offers several advantages over many commercial assays currently in use.

Recombinant SARS-CoV-2 S1 receptor-binding domain (RBD) subunit and recombinant SARS-CoV-2 nucleocapsid protein which had been expressed in HEK293 cells were purchased from RayBiotech (Peachtree Corners, GA, USA). Human coronavirus (HCoV-229E) spike protein (S1 subunit, His Tag) and human coronavirus (HCoV-OC43) spike protein (S1 subunit, His Tag) were purchased from Sino Biological (Wayne, PA, USA). The recombinant monoclonal anti-SARS-CoV-2 spike glycoprotein S1 antibody (CR3022) was purchased from Abcam (Cambridge, MA, USA). Streptavidin ImmunoCAPs and tetanus toxoid Immuno-CAPs, as well as ImmunoCAPs to measure total IgG, were purchased from Thermo Fisher Scientific (Portage, MI, USA). Galactose-α-1,3-galactose-β-1,4-GlcNAc-HSA (3 atom spacer) was purchased from Dextra (Reading, UK).

Samples were available from 60 confirmed COVID-19 cases. De-identified plasma samples from 15 patients hospitalized with COVID-19 were available through the clinical laboratory for initial assay development carried out under the common rule. Paired serum and plasma samples were available from 36 patients with CO-VID-19 seen in outpatient post-hospitalization follow-up clinic as part of a University of Virginia (UVA) Institutional Review Board (IRB) approved investigation (HSR#200148). Serum samples were available from 17 patients at various longitudinal time points during inpatient admission for management of COVID-19 as part of a UVA IRB-approved investigation (HSR#200171), 8 of which were also seen in the outpatient follow-up clinic. Inpatient samples were collected at days 0, 1, and 7 of hospitalization. For this longitudinal cohort, the day at which the sample was collected was normalized in relation to initial symptom onset (and expressed as days after symptom onset). Serum from allergic and nonallergic adults (n = 109) obtained prior to December 2019 as part of a UVA IRBapproved investigation (#13298) were used as reference controls. All patients/participants in the IRB-approved studies provided written informed consent.

The biotin-streptavidin technique was used to link target antigens to the solid phase of the ImmunoCAP assay. Biotinylation was performed using EZ-Link Sulfo-NHS-LC-Biotin (ThermoScientific, Waltham, MA, USA). Briefly, to 500 μL of 2 mg/mL protein solution, 60 μL of 2 mg/mL of biotin was added. Mixtures were placed in the dark and incubated for 4 h at room temperature. The biotinylated proteins were dialyzed against PBS at 4°C for 24 h with 3 buffer changes. In initial optimization experiments, different amounts of biotinylated spike-RBD and nucleocapsid proteins were conjugated to the solid phase (4, 2, 1, 0.5, and 0.25 μg). Subsequent experiments used 1.25 μg of SARS-CoV-2 protein to prepare each ImmunoCAP. For the α-Gal assay, 2 μg of biotinylated α-Gal-HSA was used to prepare each ImmunoCAP. Total IgG was measured according to manufacturer's instructions using a 1:200 benchtop dilution. Assays were carried out with an ImmunoCAP 250 (Thermo Fisher Scientific), using an internal calibrator curve ranging from 2 to 200 μg/mL that is provided by the manufacturer. The accuracy of this calibrator, which is not antigen-specific, was confirmed by assaying known concentrations of the anti-SARS-CoV-2 spike glycoprotein S1 antibody (CR3022) using spike-RBD ImmunoCAPs.

Antibody levels were non-normally distributed and were compared by Mann-Whitney U test. The cutoff threshold of the assay Quantitative Measurement of IgG to SARS-CoV-2 3 Int Arch Allergy Immunol DOI: 10.1159/000514203 as well as sensitivity and specificity of the assay for spike-RBD and nucleocapsid was determined using receiver operating characteristic curve analysis. Correlation between concentration of the monoclonal antibody CR3022 and assay readout were determined using simple linear regression. All analyses were performed using GraphPad Prism V8.4 (San Diego, CA, USA).

The assay was initially developed using plasma from 15 de-identified patients hospitalized with COVID-19 who had been confirmed to have IgG to SARS-CoV-2 with the FDA-EUA-approved Abbott Architect i2000 immunoassay. To measure IgG antibody to SARS-CoV-2, streptavidin-linked immunosorbents were prepared using 1.25 μg of biotinylated spike-RBD or nucleocapsid protein, as determined in preliminary optimization experiments (see online suppl. Fig. 1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000514203). Dilution curves carried out at 1:100, 1:500, 1:2,500, 1:12,500, and 1:62,500 (accounting for the 1:100 onboard dilution) exhibited parallelism for both SARS-CoV-2 proteins (Fig. 1a) . Observed values with the nucleocapsid ImmunoCAP assay generally aligned with the results of the Abbott assay, which used nucleocapsid on the solid phase, in a head-to-head comparison (Fig. 1b) . Initial results using matched plasma and serum from seroconverted patients showed negligible differences, demonstrating both types of specimens can be used in this assay (online suppl. Fig. 2 ). To confirm the quantitative accuracy of the assay, we utilized a monoclonal anti-SARS-CoV-2 spike S1 IgG1 antibody (CR3022) [5] . The concentration of CR3022 mAb [5] used in the assay correlated closely with the assay readout (R 2 = 0.97, p < 0.001) (Fig. 1c) .

To determine an optimal cutoff limit and nonspecific binding in the assay, samples from COVID-19 patients (n = 51) and samples from allergic and nonallergic donors banked prior to the emergence of COVID-19 (n = 109) were assayed using ImmunoCAPs conjugated with SARS-CoV-2 protein and also unconjugated "naked" streptavidin ImmunoCAPs. The COVID-19 samples were obtained from the 15 hospitalized patients described above, as well as 36 patients evaluated in an outpatient follow-up clinic following hospitalization for COVID-19 [18] . IgG binding to naked streptavidin ImmunoCAPs was observed at low levels in both COVID-19 and pre-CO-VID-19 samples (online suppl. Fig. 3 ). To account for this background binding, the result obtained with the streptavidin ImmunoCAP was henceforth subtracted from the result obtained using viral antigen for each sample that was assayed. At a cutoff threshold of 2.5 μg/mL, the assay had 100% sensitivity and 99% specificity in receiver operating characteristic curve analysis for both the spike-RBD and nucleocapsid assay (Fig. 1d) . Of note, this value is only marginally different from the value of 2 μg/mL, which is the lower end of the assay's measuring range according to the manufacturer's instructions and within the range in which the assay exhibited parallelism in dilution experiments (Fig. 1a) .

Next, we used the assay to measure IgG antibodies to SARS-CoV-2 proteins in 17 patients hospitalized with a primary diagnosis of COVID-19 in which longitudinal blood draws were available. None of these patients had received convalescent plasma and the majority had severe disease as reflected by admission to the intensive care unit and a requirement of mechanical ventilation (online suppl. Table 1 ). Among these patients, the seroconversion rate was 88% for spike-RBD (15 of 17 patients) and 83% for nucleocapsid (14 of 17 patients), considering the whole duration of the study (Fig. 2a, b) . Of note, none of the patients who failed to seroconvert had samples available at time points later than 14 days post-symptom onset. IgG to both spike-RBD and nucleocapsid proteins generally occurred in parallel, were positive within 10-12 days after the onset of symptoms and decreased over time (Fig. 2c) .

We next sought to determine how levels of IgG to SARS-CoV-2 (spike-RBD) in the subacute (defined as day 14-28 post-symptom onset) and convalescent (posthospitalization, median = 70 days post-symptom onset) phase compared to baseline levels of IgG to the spike S1 protein of 2 non-SARS coronaviruses (HCoV). We focused on HCoV-229E and HCoV-OC43 as these 2 coronaviruses represent important causes of community upper respiratory viral infections [19] . We also assessed 2 reference antigens that were expected to be recognized by high levels of IgG. Tetanus toxoid represents an antigen to which most individuals are routinely immunized and galactose-α-1,3-galactose (α-Gal) is an oligosaccharide of nonprimate mammals which is the target of abundant IgG in immunocompetent humans [20] . The results revealed that levels of IgG to SARS-CoV-2 in patients with severe COVID (in the subacute and convalescent phase) were higher than levels of IgG specific for HCoV-OC43 and HCoV-229E, and also tetanus toxoid or α-Gal (Mann-Whitney, p < 0.01 for each comparison) (Fig. 3a) . Total IgG levels trended higher in the COVID-19 patients, but this did not achieve significance (Mann-Whitney, p = 0.16). Responses to SARS-CoV-2 in the subacute phase represented nearly 1% of total IgG (Fig. 3b) . Interestingly, IgG to α-Gal represented <0.1% of total IgG in both cases and controls, a level lower than previously reported [20] . Finally, this analysis allowed us to explore the effects of preexisting immunity to HCoV on the magnitude of IgG to SARS-CoV-2 that developed in COVID-19 patients. Baseline levels of IgG to HCoV-229E and HCoV-OC43 spike S1 were paired with the highest value for IgG to SARS-CoV-2 that was observed in the subacute phase. Samples with the lowest levels of IgG to HCoV-229E and HCoV-OC43 appeared to have relatively higher levels of IgG to SARS-CoV-2, though this analysis was limited by sample size considerations (Fig. 3c ).

The majority of serologic studies of COVID-19, and also commercial assays for measuring IgG to SARS-CoV-2, have been limited by a lack of quantitative information about antiviral antibodies in standardized units. Here, we have shown that the ImmunoCAP assay, which is well known for its strong performance characteristics for IgE measurement and is used in clinical and research labs across the globe, can be readily adapted for the quantitative measurement of IgG to SARS-CoV-2 proteins. In the current study, the assay has high sensitivity and specificity and, unlike the majority of commercial assays, has a readout in standardized units (µg/mL). A particular strength of the approach is that up to 20 separate assays, including assays that use novel antigens that have been linked to the solid phase by the biotin-streptavidin technique, can be run in parallel using a single 20 μL sample. Applying the assay, we have shown that peak levels of IgG to SARS-CoV-2 spike-RBD and nucleocapsid can approach or exceed 100 μg/mL, equivalent to ∼1% of total IgG, in the subacute phase of infection before waning over time. This level significantly exceeded steady-state levels that were detected to major representative antigens, that is, IgG to tetanus toxoid, α-Gal, and also to HCoV. The timing and trajectory of anti-SARS-CoV-2 IgG in our assay generally fit with prior reports, with levels peaking within 3 weeks of symptom onset and showing a significant decrease within 3 months [5, 8, 21, 22] . Although preliminary, our data also suggest that preexisting immu-nity to HCoV could affect the development of IgG to SARS-CoV-2.

The current investigation of COVID-19 cases primarily included serum/plasma samples from those cases that were severe, as reflected by intensive care admission status and mechanical ventilation history. We acknowledge that the performance characteristics of the assay may differ when studying mild or asymptomatic COVID-19 cases.

To date, we have not compared the results from Immuno-CAP with results of neutralizing antibody assay. This is an important next step, however, other groups have convincingly reported that IgG to spike-RBD correlates with results using neutralization assays [23, 24] . Our data also suggests that nonspecific binding (background) in this system is ∼1-3 μg/mL. This may be higher than background values observed in other assay systems; however, we have addressed this by accounting for binding to unconjugated streptavidin ImmunoCAPs for each sample. Acknowledging these limitations, the assay we have described has several strengths compared to many of the serological approaches currently being used in COVID-19 research and patient care. The ImmunoCAP-based assay we have described can readily be adapted to study IgG to SARS-CoV-2 and also many other antigens by using commercially available ImmunoCAPs or the streptavidin-biotin technique. The assay has good performance characteristics, has a quantitative readout in standardized units, and could be used by laboratories across the globe that routinely uses the ImmunoCAP [25] .

An interactive web-based dashboard to track COVID-19 in real time

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A Novel coronavirus from patients with pneumonia in China

A serological assay to detect SARS-CoV-2 seroconversion in humans

Rapid decay of Anti-SARS-CoV-2 antibodies in persons with mild covid-19

An mRNA vaccine against SARS-CoV-2: preliminary report

Head-to-head comparison of two SARS-CoV-2 serology assays

Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in Nashville

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests

Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma

Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays

Pomés A. Technological innovations for highthroughput approaches to in vitro allergy diagnosis

Specific IgG4 antibodies to cow's milk proteins in pediatric patients with eosinophilic esophagitis

Immu-noCAP assays: pros and cons in allergology

Quantitative measurement of IgE antibodies to purified allergens using streptavidin linked to a high-capacity solid phase

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

Post-intensive care unit COVID-19 outcomes: a case series

Lessons for COVID-19 immunity from other coronavirus infections

Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature

Quantitative measurement of IgG to SARS-CoV-2 proteins using ImmunoCAP. medRxiv

The authors thank William Petri, Pat Pramoonjago, Deborah Murphy, and colleagues affiliated with the UVA COVID-19 Biorepository and clinical research teams; Jonas Lidholm at Thermo Fisher Scientific for helpful conversations about ImmunoCAP assay development; and Christopher Moskaluk and Lindsay Bazydlo for facilitating access to samples from the clinical laboratory. Current address of Joesph R. Wiencek is Department of Pathology, Immunology, and Microbiology, Vanderbilt University School of Medicine, Nashville, TN.

A preprint version of the manuscript is available at medRxiv, DOI: https://doi.org/10.1101/2020.11.09.20228411. This study was approved by the IRB for Health Sciences Research at the UVA. All patients/participants in the IRB-approved studies provided written informed consent.

T.P.M. has a patent on an IgE assay to α-Gal and has received assay support from Thermo Fisher Scientific. J.W. has received consultant fees and assay support from Thermo Fisher Scientific. The other authors have no conflicts of interest to declare.